Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab in Combination With Allogeneic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer

NCT01896869 is registered in ClinicalTrials.gov with Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as lead sponsor.

NCT NCT01896869
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01896869 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab in Combination With Allogeneic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2013
Completion date
May 3, 2019
Enrollment
83 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic adenocarcinoma